Literature DB >> 25648524

Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.

Arjen H G Cleven1, Evita Zwartkruis1, Pancras C W Hogendoorn1, Herman M Kroon2, Inge Briaire-de Bruijn1, Judith V M G Bovée1.   

Abstract

AIMS: Periosteal chondrosarcoma is a rare, malignant cartilage-forming neoplasm originating from the periosteal surface of bone. We collected 38 cases from the archives of the Netherlands Committee on Bone Tumours, with the aim of studying histological features and evaluating the involvement of isocitrate dehydrogenase 1 (IDH1), EXT, Wnt/β-catenin, the pRB pathway (CDK4 and p16), and the TP53 pathway (p53 and MDM2). METHODS AND
RESULTS: Histology showed a moderately cellular matrix with mucoid-myxoid changes and, in 42% of cases, formation of a neocortex. Occasional intramedullary extension (26%) and subsequent host bone entrapment (40%) were seen. Histological grading revealed grade 1 (53%) and grade 2 (45%). The EXT1 protein was normally expressed, and mutations in IDH1 were observed in only 15% of cases. pRb signalling was deregulated by loss of p16 expression in 50% of cases, and Wnt signalling was lost in 89%. No alterations were found in CDK4, p53, or MDM2.
CONCLUSIONS: We report the first large histological and molecular study on periosteal chondrosarcoma showing that histopathological examination and molecular aberrations do not predict prognosis. Although the mutation frequency of IDH1 was low, we confirm the supposed relationship with central chondrosarcoma. Moreover, we identify loss of canonical Wnt signalling and deregulation of pRb signalling as possible events contributing to its histogenesis.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  IDH1; bone tumour; chondrosarcoma; periosteal chondrosarcoma

Mesh:

Substances:

Year:  2015        PMID: 25648524     DOI: 10.1111/his.12666

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

Review 1.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

Review 2.  The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.

Authors:  Inga-Marie Schaefer; Jason L Hornick; Judith V M G Bovée
Journal:  Lab Invest       Date:  2018-01-16       Impact factor: 5.662

3.  Traumatic Glenosphere Dissociation Following Reverse Total Shoulder Endoprosthetic Reconstruction for Proximal Humerus Periosteal Chondrosarcoma: A Case Report.

Authors:  Michael M Chau; Erick M Marigi; Zac B Novaczyk; Allan F Hunt; Jeffrey T Luna
Journal:  J Orthop Case Rep       Date:  2020-11

4.  Secondary peripheral chondrosarcoma arising in solitary osteochondroma: variables influencing prognosis and survival.

Authors:  Alberto Righi; Marina Pacheco; Stefania Cocchi; Sofia Asioli; Marco Gambarotti; Davide Maria Donati; Andrea Evangelista; Maria Gnoli; Manuela Locatelli; Marina Mordenti; Manila Boarini; Evelise Brizola; Elena Pedrini; Luca Sangiorgi
Journal:  Orphanet J Rare Dis       Date:  2022-02-22       Impact factor: 4.123

5.  Clinical, Radiological, and Histopathological Characteristics of Periosteal Chondrosarcoma with a Focus on the Frequency of Medullary Invasion.

Authors:  Makoto Nakagawa; Makoto Endo; Yosuke Susuki; Nobuhiko Yokoyama; Akira Maekawa; Akira Nabeshima; Keiichiro Iida; Toshifumi Fujiwara; Nokitaka Setsu; Tomoya Matsunobu; Yoshihiro Matsumoto; Ryohei Yokoyama; Yuichi Yamada; Kenichi Kohashi; Hidetaka Yamamoto; Yoshinao Oda; Yukihide Iwamoto; Yasuharu Nakashima
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

Review 6.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 7.  Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.

Authors:  Katia Scotlandi; Claudia Maria Hattinger; Evelin Pellegrini; Marco Gambarotti; Massimo Serra
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.